activin A receptor like type 1
Last updated 20 May 2021
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Audio Version
- Add to preferred sources on Google
The ACVRL1 gene provides instructions for making a protein called activin receptor-like kinase 1. This protein is found on the surface of cells, especially in the lining of developing arteries.
Normal function
The ACVRL1 gene provides instructions for making a protein called activin receptor-like kinase 1. This protein is found on the surface of cells, especially in the lining of developing arteries.
The ACVRL1 protein is a receptor. It acts as a "lock" waiting for a specific protein, called its ligand, to serve as the "key." In the case of the ACVRL1 protein, the ligand is called transforming growth factor beta. The interaction between these proteins plays a role in the development of blood vessels. In particular, this protein interaction is involved in the specialization of new blood vessels into arteries or veins.
Conditions referring to this gene or chromosome
Other names
activin A receptor type II-like 1
activin A receptor type IL
Activin A receptor, type II-like kinase 1
ACVL1_HUMAN
ACVRLK1
ALK-1
ALK1
EC 2.7.1.37
HHT
HHT2
ORW2
Serine/threonine-protein kinase Receptor R3 Precursor
SKR3
TGF-B Superfamily Receptor Type I
Related patient information and medicines
Patient information leaflet
Nausea medicine
Various medicines are available to treat nausea. Listed below are some of the more commonly prescribed medicines: Cinnarizine , cyclizine , promethazine - these medicines belong to a group of medicines called antihistamines. Th... It is thought that antihistamines block histamine 1 (H1) receptors in the area of the brain which creates nausea in.
Patient information leaflet
Myasthenia gravis
Myasthenia gravis (MG) is a condition where muscles become easily tired and weak. It is due to a problem with how... What causes myasthenia gravis. Myasthenia gravis is an autoimmune disease. This means that the immune system (which normally protects the body from infections) mistakenly attacks itself. (Other autoimmune diseases include type 1.
Patient information leaflet
Can I take Alogliptin and Rybelsus together?
Taking alogliptin and Rybelsus (semaglutide) together can significantly increase the risk of your blood sugar dropping too low (hypoglycaemia). Alogliptin (a DPP-4 inhibitor) prevents the breakdown of natural hormones that lower blood sugar, while Rybelsus (a GLP-1 receptor agonist) mimics those same hormones. Using both is like 'doubling up' on.
Patient information leaflet
Diabetes and illness
. Sick day diabetes guidelines The following guidance is provided by Diabetes UK: Contact your general practice or diabetes team who will help you if you have any queries or if you are unsure about what to do. There is also further information in the following sections on Type 1 diabetes and Type 2 diabetes. On GLP-1 receptor agonists (.
Patient information leaflet
Insulin
Insulin is a hormone made naturally in the body by the pancreas. This hormone controls the level of sugar (glucose) in the blood. People with diabetes need treatment to control the level of sugar (glucose) in their blood. There are two different types of diabetes: Type 1 diabetes Type 1 diabetes is the type of diabetes that typically develops in.
Patient information leaflet
Type 2 diabetes
Type 2 diabetes can occur at any age, including during childhood, but it occurs mainly in people aged over 40. What is type 2 diabetes. Type 2 diabetes and its symptoms tend to develop gradually (over weeks or months). This is because in type 2 diabetes you still make insulin (unlike in type 1 diabetes ). However, you develop type 2 diabetes.
Further reading and references
- activin A receptor like type 1; MedlinePlus, National Library of Medicine.
- Azuma H. Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J Med Invest. 2000 Aug;47(3-4):81-90.
- Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005 Feb 15;65(3):599-608. doi: 10.1016/j.cardiores.2004.10.036.
- Lesca G, Plauchu H, Coulet F, Lefebvre S, Plessis G, Odent S, Riviere S, Leheup B, Goizet C, Carette MF, Cordier JF, Pinson S, Soubrier F, Calender A, Giraud S; French Rendu-Osler Network. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat. 2004 Apr;23(4):289-99. doi: 10.1002/humu.20017.
- Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, Lindhout D, Hennekam FA, Westermann CJ, Ploos van Amstel JK. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet. 2005 Jan;116(1-2):8-16. doi: 10.1007/s00439-004-1196-5. Epub 2004 Oct 23.
- Pawlikowska L, Tran MN, Achrol AS, Ha C, Burchard E, Choudhry S, Zaroff J, Lawton MT, Castro R, McCulloch CE, Marchuk D, Kwok PY, Young WL; UCSF BAVM Study Project. Polymorphisms in transforming growth factor-beta-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke. 2005 Oct;36(10):2278-80. doi: 10.1161/01.STR.0000182253.91167.fa. Epub 2005 Sep 22.
- van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res. 2003 Apr 1;58(1):20-31. doi: 10.1016/s0008-6363(02)00852-0.
Join the conversation
Share your thoughts or experiences with others in our patient communities.
Ask, share, connect.
Browse discussions, ask questions, and share experiences across hundreds of health topics.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.